Boston Immune Technologies And Therapeutics Inc.

Winchester, MA

UEI
MWNARWHZWRM5
CAGE
7P7S2
Primary NAICS
541711 Research and Development in Biotechnology
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
81 Walnut St, Winchester, MA 01890, USA
Website
bostonimmunetech.com

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Advancing bitt-101 a novel dominant CD40 antagonist for use in treatment of sjogren syndrome. R44AI179385 National Institute of Allergy and Infectious Diseases (NIH) $2,215,150
Preclinical toxicology and pharmacology evaluation of a NEWTNFR2 antagonistic monoclonal antibody for ctcl therapy R44CA265510 National Cancer Institute (NIH) $14,384,953

Quick answers

Is Boston Immune Technologies And Therapeutics Inc. registered in SAM.gov?

Yes. Boston Immune Technologies And Therapeutics Inc.'s SAM.gov registration is active through July 9, 2027.

What is Boston Immune Technologies And Therapeutics Inc.'s most recent federal award?

Boston Immune Technologies And Therapeutics Inc.'s most recent federal grant award is Advancing bitt-101 a novel dominant CD40 antagonist for use in treatment of sjogren syndrome (R44AI179385), from National Institute of Allergy and Infectious Diseases (NIH), on August 21, 2023.

On GovTribe

See Boston Immune Technologies And Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login